- Home
- OKYO vs LTRN Comparison
OKYO vs LTRN Comparison
Compare OKYO & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- LTRN
- Stock Information
- Founded
- OKYO 2007
- LTRN 2013
- Country
- OKYO United Kingdom
- LTRN United States
- Employees
- OKYO N/A
- LTRN N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- LTRN Health Care
- Exchange
- OKYO Nasdaq
- LTRN Nasdaq
- Market Cap
- OKYO 38.2M
- LTRN 36.2M
- IPO Year
- OKYO 2022
- LTRN 2020
- Fundamental
- Price
- OKYO $1.11
- LTRN $3.50
- Analyst Decision
- OKYO Strong Buy
- LTRN Hold
- Analyst Count
- OKYO 1
- LTRN 1
- Target Price
- OKYO $7.00
- LTRN N/A
- AVG Volume (30 Days)
- OKYO 128.1K
- LTRN 43.0K
- Earning Date
- OKYO 11-22-2024
- LTRN 11-07-2024
- Dividend Yield
- OKYO N/A
- LTRN N/A
- EPS Growth
- OKYO N/A
- LTRN N/A
- EPS
- OKYO N/A
- LTRN N/A
- Revenue
- OKYO N/A
- LTRN N/A
- Revenue This Year
- OKYO N/A
- LTRN N/A
- Revenue Next Year
- OKYO N/A
- LTRN N/A
- P/E Ratio
- OKYO N/A
- LTRN N/A
- Revenue Growth
- OKYO N/A
- LTRN N/A
- 52 Week Low
- OKYO $0.81
- LTRN $3.04
- 52 Week High
- OKYO $2.12
- LTRN $11.99
- Technical
- Relative Strength Index (RSI)
- OKYO 49.75
- LTRN 51.26
- Support Level
- OKYO $1.07
- LTRN $3.04
- Resistance Level
- OKYO $1.30
- LTRN $3.87
- Average True Range (ATR)
- OKYO 0.09
- LTRN 0.23
- MACD
- OKYO -0.01
- LTRN 0.04
- Stochastic Oscillator
- OKYO 18.52
- LTRN 60.84
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.